• Overview
  • Eligibility
  • More info
  • Locations

A Randomized Controlled Trial of Midodrine During Recovery Phase From Septic Shock (NCT02771158)

The purpose of this study is to determine whether midodrine administration decreases duration of intravenous vasopressors and intensive care unit length of stay for patients in septic shock.
  • Drug: Midodrine
    midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
    • proamatine
  • Drug: placebo
    placebo will be administered to double blind the study
    Ages eligible for Study
    18 Years and older
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    No
    Inclusion Criteria:
    • admitted to intensive care unit
    • diagnosis of septic shock on intravenous vasopressors
    • stable/decreasing doses of intravenous vasopressors
    • stable/improving organ function
    Exclusion Criteria:
    • allergy to midodrine
    • multiple intravenous vasopressors
    • increasing intravenous vasopressor requirements
    • worsening organ dysfunction
    • severe bradycardia
    Status:
    withdrawn
    Type:
    Interventional
    Phase:
    Start:
    31 July, 2017
    Updated:
    31 October, 2017
    Participants:
    0
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!